

# Newsletter



European  
Reference  
Network

Genetic Tumour Risk Syndromes  
(ERN GENTURIS)

May 2020 | [www.genturis.eu](http://www.genturis.eu)

## Successful first webinar by Maurizio Genuardi

ERN GENTURIS successfully launched her series of monthly educational webinars on Wednesday, 15 April, with a webinar on 'The Heritability of Cancer' presented by Prof. Maurizio Genuardi (Gemelli University Hospital, Rome, Italy) and moderated by Dr. Hildegunn Vetti (Haukeland University Hospital, Bergen, Norway). Close to 400 attendants joined the webinar.

The recording of the webinar is now available via our [genturis website](http://www.genturis.eu).

---

### webinar: Hereditary Breast and Ovarian Cancer – BRCA1, BRCA2 and the basics

**20 May, 16:00-16:45 CEST**

**Dr. Marc Tischkowitz, Cambridge**

Dr. Marc Tischkowitz from the University of Cambridge will share his expertise during the second webinar, which will take place on 20 May, 16:00.



BRCA1 and BRCA2 are two of the most important genes in inherited cancer predisposition. They are probably the most sequenced and characterised genes in clinical medicine, but many unanswered questions remain.

This webinar will provide an overview of these genes from their discovery in the mid 90's to the current day. It will focus on the known cancer predisposition spectrum, cancer risk estimates, the development of mainstream testing and current controversies in the management of individuals who carry pathogenic variants in these genes. If you would like to join this webinar, please [register here](#).

---

## webinar: The Genetic Basis of Cancer

17 June, 16:00-16:45 CEST

Prof. Dr. Marjolijn Ligtenberg,  
Nijmegen

Prof. dr. Marjolijn Ligtenberg, professor in molecular tumour genetics at Radboud university medical center Nijmegen, The Netherlands, will give the monthly webinar in June with a lecture on the genetic basis of cancer.



In this webinar it will be discussed that cancer is a genetic disease although mostly not heritable. All cancers have genetic aberrations that drive the tumorigenesis. Knowing these driving forces may help in selection of therapeutic strategies, differential diagnosis and assessment of tumour risk syndromes. A variety of genetic aberrations and their relevance for clinical management and identification of genetic tumour risk syndromes will be addressed. If you would like to join this webinar, please [register here](#).

---

## European webpage on ERNs and COVID-19

The European Commission published a [European webpage on the ERNs and COVID-19](#). This page provides a description of the COVID-19 Clinical Management Support System (CMSS), the statement by the ERN Board of Member states and the eNews. This page will become available in all EU languages shortly.

### How to unsubscribe?

You received this newsletter because you are a contact of ERN GENTURIS. If you no longer wish to receive newsletters, please [unsubscribe](#).

ERN GENTURIS Coordinating Center:  
Radboud university medical center  
The Netherlands

[genturis@radboudumc.nl](mailto:genturis@radboudumc.nl)

<https://www.genturis.eu>

[Unsubscribe](#)

